Claims for Patent: 8,507,505

Summary for Patent: 8,507,505

Title:	Dihydropyrazolopyrimidinone derivative
Abstract:	The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar.sup.1 is an optionally substituted aryl or heteroaryl group; R.sup.1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R.sup.2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R.sup.3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy. ##STR00001##
Inventor(s):	Bamba; Makoto (Ibaraki, JP), Furuyama; Hidetomo (Kanagawa, JP), Sakamoto; Toshihiro (Ibaraki, JP), Sunami; Satoshi (Ibaraki, JP), Takahashi; Keiji (Chiba, JP), Yamamoto; Fuyuki (Ibaraki, JP), Yoshizumi; Takashi (Ibaraki, JP)
Assignee:	MSD K.K. (Chiyoda-Ku, Tokyo, JP)
Application Number:	13/133,673
Patent Claims:	1. A compound of Formula (I-I): ##STR00131## or a pharmaceutically acceptable salt, wherein Q1 is a single bond, or a C1-C6 alkylene group, in which one or two or more methylene groups constituting the C1-C6 alkylene group may be independently replaced with an oxygen atom, a sulfur atom, a carbonyl group, an imino group, a sulfinyl group or a sulfonyl group, and may be substituted with a halogen atom, a cyano group, a hydroxyl group, a C1-C6 alkyl group or a C1-C6 alkoxy group; R1a is a hydrogen atom, a hydroxyl group, a formyl group, a C1-C6 alkyl group, a di-C1-C6 alkylamino group, a hydroxy-C1-C6 alkyl group or a carboxyphenyl group, or a heterocyclic group, wherein said heterocyclic group means a monocyclic or bicyclic heterocyclic group formed of 3 to 7 carbon atoms in each ring and containing one or two nitrogen atoms, wherein said heterocyclic group may be aromatic or aliphatic, and which may have a substituent selected from the group consisting of a halogen atom, a hydroxyl group, an oxo group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxy-C1-C6 alkyl group, a C1-C6 alkoxy-C1-C6 alkyl group, and a group represented by --R1b; R1b is a group represented by -Q2-A1 (R1c)R1d; Q2 is a single bond, or a C1-C6 alkylene group, in which one or two or more methylene groups constituting the C1-C6 alkylene group may be independently replaced with an oxygen atom, a sulfur atom, a carbonyl group, an imino group, a sulfinyl group or a sulfonyl group, and may be substituted with a halogen atom, a cyano group, a hydroxyl group, an imino group, a C1-C6 alkyl group or a C1-C6 alkoxy group; A1 is a nitrogen atom, or a methine group which may be substituted with a hydroxyl group, a C1-C6 alkyl group or a hydroxy-C1-C6 alkyl group; R1c and R1d are independently a hydrogen atom, a carboxyl group, a C1-C6 alkyl group, or a hydroxy-C1-C6 alkyl group, or together represent a C1-C6 alkylene group, in which one or two or more methylene groups constituting the C1-C6 alkylene group may be independently replaced with an oxygen atom, a sulfur atom, a sulfonyl group, a sulfonyl group, a carbonyl group, a vinylene group or a group represented by --N(R1e)-, and may be substituted with a hydroxyl group, a C1-C6 alkyl group or a hydroxy-C1-C6 alkyl group; R1e is a hydrogen atom, a formyl group, an acetyl group or a C1-C6 alkyl group; R1 is a hydrogen atom; a C1-C6 alkyl group which may have a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkoxy group, a C3-C6 cycloalkyl group, a C2-C7 alkanoyl group and a C1-C6 alkylsulfonyl group; or an aryl, aralkyl, or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, an amino group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkyl group and a hydroxy-C1-C6 alkyl group; R2 is an aryl, aralkyl or heteroaryl group, wherein said heteroaryl group means a 5 or 6 membered monocyclic heteroaryl group having one to three heteroatoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom, or a condensed-ring heteroaryl group formed by the condensation of the monocyclic heteroaryl group and the aryl group or by the condensation of the monocyclic heteroaryl groups, which may be the same or different, and which may have a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, a carbamoyl group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylsulfonyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group and a C1-C6 alkoxy-C1-C6 alkyl group; and R4 and R5 are independently a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a hydroxy-C1-C6 alkylamino group, a carbamoyl group, or a hydroxy-C1-C6 alkylcarbamoyl group. 2. The compound of claim 1, or a pharmaceutically acceptable salt, wherein R2 is a group represented by the Formula (a) ##STR00132## wherein R2a is a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, a carbamoyl group, a C1-C6 alkyl group, a C1-C6 alkylsulfonyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group or a C1-C6 alkoxy-C1-C6 alkyl group; and T, U, V and W are a nitrogen atom, or a methine group which may be substituted with a halogen atom, a hydroxyl group, a cyano group, an amino group, a nitro group, a carbamoyl group, a C1-C6 alkyl group, a C1-C6 alkylsulfonyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group and a C1-C6 alkoxy-C1-C6 alkyl group, wherein at least two of them are the methine groups. 3. The compound of claim 2, or a pharmaceutically acceptable salt, wherein R2 is a group represented by the Formula (a), R2a is a halogen atom, and T is a methine group substituted with a halogen atom or a C1-C6 alkyl group. 4. The compound of claim 3, or a pharmaceutically acceptable salt, wherein R2 is a 2,6-dichlorophenyl group. 5. The compound of claim 1, or a pharmaceutically acceptable salt, wherein R1 is a hydrogen atom, or a C1-C6 alkyl group which may be substituted with a halogen atom or a hydroxyl group. 6. The compound of claim 1, or a pharmaceutically acceptable salt, wherein R1 is a hydrogen atom, or a C1-C6 alkyl group which may be substituted with a hydroxyl group; and the group represented by -Q1-R1a is a group selected from the groups represented by the Formulae (a1): ##STR00133## wherein one or two or more methylene groups constituting said group may be independently substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl group, an oxo group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxy-C1-C6 alkyl group, a C1-C6 alkoxy-C1-C6 alkyl group and a group represented by --R1b; R10a is a hydrogen atom, a C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group or a group represented by --R1b. 7. The compound of claim 6, or a pharmaceutically acceptable salt, wherein R1b is a group represented by -Q2-A1(R1c)R1d, in which: (i) Q2 is a single bond, A1 is a nitrogen atom, and R1c and R1d are independently a hydrogen atom or a C1-C6 alkyl group; (ii) Q2 is a single bond, or a C1-C6 alkylene group, in which one of the methylene groups constituting the C1-C6 alkylene group may be replaced with a carbonyl group, A1 is a methine group, and R1c and R1d are hydrogen atoms; (iii) Q2 is a C1-C6 alkylene group, in which one of the methylene groups constituting the C1-C6 alkylene group may be replaced with an oxygen atom or a carbonyl group, or may be substituted with a C1-C6 alkyl group, A1 is a nitrogen atom, and R1c and R1d are independently C1-C6 alkyl groups; or (iv) Q2 is a single bond, A1 is a methine group, and R1c and R1d together represent a C1-C6 alkylene group, in which one of the methylene groups constituting the C1-C6 alkylene group may be replaced with a group represented by --N(R1e)-. 8. The compound of claim 1, which is: (1) 3-(2,6-dichlorophenyl)-7-({4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl}ami- no)-4-imino-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (2) 3-(2,6-dichlorophenyl)-7-({4-[2-(hydroxymethyl)morpholin-4-yl]phenyl}amin- o)-4-imino-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (3) 3-(2,6-dichlorophenyl)-7-[(4-{4-[(dimethylamino)acetyl]piperazin-1-yl}phe- nyl)amino]-4-imino-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (4) 3-(2,6-dichlorophenyl)-7-[(4-{2-[(dimethylamino)methyl]morpholin-4-yl- }phenyl)amino]-4-imino-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-- one; (5) 3-(2,6-dichlorophenyl)-4-imino-7-{[4-(4-methylpiperazin-1-yl)phen- yl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (6) 3-(2,6-dichlorophenyl)-4-imino-7-{[3-methyl-4-(4-methylpiperazin-1-yl)phe- nyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (7) 3-(2,6-dichlorophenyl)-4-imino-1-methyl-7-{[4-(4-methylpiperazin-1-yl)phe- nyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (8) 3-(2,6-dichlorophenyl)-7-({4-[(3R)-3-dimethylaminopyrrolidin-1-yl]phenyl}- amino)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (9) 3-(2,6-dichlorophenyl)-4-imino-7-{[4-(5-methylhexahydropyrrolo[3,4-b]pyrr- ol-1(2H)-yl)phenyl}amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (10) 3-(2,6-dichlorophenyl)-4-imino-7-{[4-(2-methyl-2,7-diazaspiro[4,5]de- c-7-yl)phenyl}amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (11) 3-(2,6-dichlorophenyl)-4-imino-7-{[4-(1-methylhexahydropyrrolo[3,4-b]pyrr- ol-5(1H)-yl)phenyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (12) 3-(2,6-dichlorophenyl)-4-imino-7-({4-[(2R)-2-(methoxymethyl)-4-methy- lpiperazin-1-yl]phenyl}amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-on- e; (13) 7-({4-[3-(tert-butylamino)pyrrolidin-1-yl]phenyl}amino)-3-(2,6-dic- hlorophenyl)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (14) 3-(2,6-dichlorophenyl)-7-({4-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]pheny- l}amino)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (15) 7-{[4-(4-acetylpiperazin-1-yl)-3-methylphenyl]amino}-3-(2,6-dichloropheny- l)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (16) 3-(2,6-dichlorophenyl)-4-imino-7-{[4-(2-methyl-2,7-diazaspiro[3,5]non-7-y- l)phenyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (17) 7-({4-[4-(1-acetylazetidin-3-yl)piperazin-1-yl]phenyl}amino)-3-(2,6-dichl- orophenyl)-4-imino-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (18) 3-(2,6-dichlorophenyl)-4-imino-7-{[4-(morpholin-4-yl)phenyl]amino}-3- ,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (19) 3-(2,6-dichlorophenyl)-7-({4-[2-(dimethylamino)-1-methylethoxy]phenyl}ami- no)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (20) 3-(2,6-dichlorophenyl)-4-imino-7-({4-[methyl(pyridin-2-ylmethyl)amino]phe- nyl}amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (21) 3-(2,6-dichlorophenyl)-7-({4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl}ami- no)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (22) 3-(2,6-dichlorophenyl)-7-({4-[2-(dimethylamino)propoxy]phenyl}amino)-4-im- ino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (23) 3-(2,6-dichlorophenyl)-7-[(4-{2-[(dimethylamino)methyl]morpholin-4-yl}phe- nyl)amino]-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (24) 3-(2,6-dichlorophenyl)-7-({3-[3-(dimethylamino)propoxy]-4-methoxyphenyl}a- mino)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (25) 3-(2,6-dichlorophenyl)-7-({4-[(dimethylamino)methyl]phenyl}amino)-4-imino- -3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; (26) 3-(2,6-dichlorophenyl)-7-({4-[3-(dimethylamino)-3-(hydroxymethyl)pyrrolid- in-1-yl]phenyl}amino)-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-on- e; (27) 3-(2,6-dichlorophenyl)-7-[(4-{1-[2-(dimethylamino)ethyl]-1H-pyrazo- l-4-yl}phenyl)amino]-4-imino-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one- ; or (28) 3-(2,6-dichlorophenyl)-1-(2-hydroxyethyl)-4-imino-7-{[4-(4-methy- lpiperazin-1-yl)phenyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-on- e, or a pharmaceutically acceptable salt thereof. 9. A pharmaceutical composition which comprises a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier or diluent. 10. A method of treating a Wee1 kinase mediated cancer, wherein said cancer is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, colon cancer, ovarian cancer, acute leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and Hodgkin's lymphoma, with a therapeutically effective amount of the pharmaceutical composition of claim 9 to a mammal in need thereof. 11. A combined preparation for simultaneous, separate or successive administration in cancer therapy, comprising the following two separate preparations (a) and (b): (a) a preparation comprising a compound of claim 1, or a pharmaceutically acceptable salt, together with a pharmaceutically acceptable carrier or diluent; and (b) a preparation comprising, together with a pharmaceutically acceptable carrier or diluent, an anticancer agent selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum coordination compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, monoclonal antibodies, interferons, biological response modifiers, and other anticancer agents, or a pharmaceutically acceptable salt, wherein the anticancer alkylating agents being nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, or carmustine, the anticancer antimetabolites being methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil, tegafur, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1, gemcitabine, fludarabine, or pemetrexed disodium, the anticancer antibiotics being actinomycin D, doxorubicin, daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer, idarubicin, sirolimus, or valrubicin, the plant-derived anticancer agents being vincristine, vinblastine, vindeshine, etoposide, sobuzoxane, docetaxel, paclitaxel, or vinorelbine, the anticancer platinum coordination compounds being cisplatin, carboplatin, nedaplatin, or oxaliplatin, the anticancer camptothecin derivatives being irinotecan, topotecan, or camptothecin, the anticancer tyrosine kinase inhibitors being gefitinib, imatinib, or erlotinib, the monoclonal antibodies being cetuximab, bevacizumab, rituximab, alemtuzumab, or trastuzumab, the interferons being interferon .alpha., interferon .alpha.-2a, interferon .alpha.-2b, interferon .beta., interferon .gamma.-1a, or interferon .gamma.-n1, the biological response modifiers being krestin, lentinan, sizofuran, picibanil, or ubenimex, and the other anticancer agents being mitoxantrone, L-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, tretinoin, alefacept, darbepoetin alfa, anastrozole, exemestane, bicalutamide, leuprorelin, flutamide, fulvestrant, pegaptanib octasodium, denileukin diftitox, aldesleukin, thyrotropin alfa, arsenic trioxide, bortezomib, capecitabine, or goserelin. 12. A pharmaceutical composition which comprises, together with a pharmaceutically acceptable carrier or diluent, the compound of claim 1, or a pharmaceutically acceptable salt, and an anticancer agent selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum coordination compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, monoclonal antibodies, biological response modifiers, and other anticancer agents, wherein the anticancer alkylating agents being nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, or carmustine, the anticancer antimetabolites being methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil, tegafur, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1, gemcitabine, fludarabine, or pemetrexed disodium, the anticancer antibiotics being actinomycin D, doxorubicin, daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer, idarubicin, sirolimus, or valrubicin, the plant-derived anticancer agents being vincristine, vinblastine, vindeshine, etoposide, sobuzoxane, docetaxel, paclitaxel, or vinorelbine, the anticancer platinum coordination compounds being cisplatin, carboplatin, nedaplatin, or oxaliplatin, the anticancer camptothecin derivatives being irinotecan, topotecan, or camptothecin, the anticancer tyrosine kinase inhibitors being gefitinib, imatinib, or erlotinib, the monoclonal antibodies being cetuximab, bevacizumab, rituximab, alemtuzumab, or trastuzumab, the interferons being interferon .alpha., interferon .alpha.-2a, interferon .alpha.-2b, interferon .beta., interferon .gamma.-1a, or interferon .gamma.-n1, the biological response modifiers being krestin, lentinan, sizofuran, picibanil, or ubenimex, and the other anticancer agents being mitoxantrone, L-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, tretinoin, alefacept, darbepoetin alfa, anastrozole, exemestane, bicalutamide, leuprorelin, flutamide, fulvestrant, pegaptanib octasodium, denileukin diftitox, aldesleukin, thyrotropin alfa, arsenic trioxide, bortezomib, capecitabine, or goserelin, or a pharmaceutically acceptable salt thereof. 13. A method of enhancing the effectiveness of radiation by administering the pharmaceutical composition of claim 9 in a mammal in need thereof. 14. The method of claim 13 which further comprises an anticancer agent wherein the anticancer agent is selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum coordination compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, monoclonal antibodies, biological response modifiers, and other anticancer agents, wherein the anticancer alkylating agents being nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, or carmustine, the anticancer antimetabolites being methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil, tegafur, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1, gemcitabine, fludarabine, or pemetrexed disodium, the anticancer antibiotics being actinomycin D, doxorubicin, daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer, idarubicin, sirolimus, or valrubicin, the plant-derived anticancer agents being vincristine, vinblastine, vindeshine, etoposide, sobuzoxane, docetaxel, paclitaxel, or vinorelbine, the anticancer platinum coordination compounds being cisplatin, carboplatin, nedaplatin, or oxaliplatin, the anticancer camptothecin derivatives being irinotecan, topotecan, or camptothecin, the anticancer tyrosine kinase inhibitors being gefitinib, imatinib, or erlotinib, the monoclonal antibodies being cetuximab, bevacizumab, rituximab, alemtuzumab, or trastuzumab, the interferons being interferon .alpha., interferon .alpha.-2a, interferon .alpha.-2b, interferon .beta., interferon .gamma.-1a, or interferon .gamma.-n1, the biological response modifiers being krestin, lentinan, sizofuran, picibanil, or ubenimex, and the other anticancer agents being mitoxantrone, L-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, tretinoin, alefacept, darbepoetin alfa, anastrozole, exemestane, bicalutamide, leuprorelin, flutamide, fulvestrant, pegaptanib octasodium, denileukin diftitox, aldesleukin, thyrotropin alfa, arsenic trioxide, bortezomib, capecitabine, or goserelin or a pharmaceutically acceptable salt thereof.

Details for Patent 8,507,505

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	THYROGEN	thyrotropin alfa	For Injection	020898	11/30/1998		2028-12-12
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-12-12
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2028-12-12
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-12-12